Patents by Inventor Herbert Lamche

Herbert Lamche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS FOR NEBULIZING AQUEOUS COMPOSITIONS CONTAINING HIGHLY CONCENTRATED INSULIN
    Publication number: 20110268668
    Abstract: A process for nebulizing highly concentrated solutions of insulin for administration by inhalation.
    Type: Application
    Filed: July 14, 2011
    Publication date: November 3, 2011
    Inventors: Herbert Lamche, Christopher John Montague Meade, Bernd Zierenberg, Ralph Christian Reimholz
  • PROCESS FOR NEBULIZING AQUEOUS COMPOSITIONS CONTAINING HIGHLY CONCENTRATED INSULIN
    Publication number: 20060239930
    Abstract: A process for nebulizing highly concentrated solutions of insulin for administration by inhalation.
    Type: Application
    Filed: July 10, 2006
    Publication date: October 26, 2006
    Inventors: Herbert Lamche, Christopher Montague Meade, Bernd Zierenberg, Ralph Reimholz
  • Process for nebulizing aqueous compositions containing highly concentrated insulin
    Publication number: 20030064032
    Abstract: A process for nebulizing highly concentrated solutions of insulin for administration by inhalation.
    Type: Application
    Filed: November 6, 2002
    Publication date: April 3, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Herbert Lamche, Christopher John Montague Meade, Bernd Zierenberg, Ralph Christian Reimholz
  • Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path
    Patent number: 5854004
    Abstract: A process is disclosed for screening substances having a modulating effect on a receptor-dependent signal transmission path in mammal cells. Test cells are used transformed with a reporter gene and with a regulatory sequence functionally linked thereto sensitive to the IP.sub.3 /DAG concentration, as well as with a coding DNA for a receptor coupled to the phospholipase effector system, in particular a G protein-coupled receptor. The use of reference cells without receptor DNA and reference cells with specificity for the adenylate cyclase effector system allows substances to be identified having potential pharmacological action and specificity for a determined receptor-dependent signal transmission path.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: December 29, 1998
    Assignee: Boehringer Ingleheim GmbH
    Inventors: Armin Peter Czernilofsky, Adolf Himmler, Christian Stratowa, Ulrike Weyer, Herbert Lamche, Renate Schafer